Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
37.95
+1.12 (+3.04%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
NASDAQ:HRMY is not too expensive for the growth it is showing.
↗
December 16, 2024
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.
Via
Chartmill
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
December 16, 2024
Via
ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
December 13, 2024
Via
ACCESSWIRE
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
↗
October 30, 2024
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders.
Via
Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
↗
October 29, 2024
HRMY earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Analyst Expectations For Harmony Biosciences's Future
↗
October 29, 2024
Via
Benzinga
Earnings Outlook For Harmony Biosciences
↗
October 28, 2024
Via
Benzinga
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
↗
October 02, 2024
Via
Benzinga
Unveiling 6 Analyst Insights On Harmony Biosciences
↗
September 10, 2024
Via
Benzinga
Analyst Expectations For Harmony Biosciences's Future
↗
August 06, 2024
Via
Benzinga
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
↗
October 29, 2024
The company is focused on developing its pipeline of sleep and epilepsy drugs.
Via
Investor's Business Daily
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
↗
September 10, 2024
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.
Via
Benzinga
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
↗
August 06, 2024
HRMY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
August 06, 2024
From
Harmony Biosciences
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
↗
June 21, 2024
Via
Benzinga
Key Takeaways From Harmony Biosciences Analyst Ratings
↗
April 30, 2024
Via
Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
↗
March 28, 2024
Via
Benzinga
7 Cheap Biotech Stocks With Major Upside Potential
↗
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
↗
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
↗
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
↗
May 14, 2024
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via
Benzinga
Topics
Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
↗
April 30, 2024
HRMY earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Analyst Ratings For Harmony Biosciences
↗
February 22, 2024
Via
Benzinga
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
↗
April 30, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
↗
April 30, 2024
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with...
Via
Benzinga
Topics
Earnings
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Updates: HRMY, MELI, SWAV
↗
February 28, 2024
Another day, another slew of quarterly update reports for our followed stocks.
Via
Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
↗
February 22, 2024
HRMY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024
From
Harmony Biosciences
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
